ALK and lung carcinoma: Studies conducted in ALK-rearranged lung cancer cell lines have shown an increment of EGFR phosphorylation in crizotinib-resistant cell lines which did not present secondary ALK mutation/up-regulation, when compared with parental crizotinib-sensitive cells, leading to a persistent activation of downstream ERK and AKT signaling.